Vitamin D supplementation in bacterial vaginosis

Authors

  • T.F. Tatarchuk SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-5498-4143
  • L.V. Kalugina SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-2263-6627
  • T.I. Kvasha SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0001-7936-2538
  • R.O. Mnevets SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; Educational and Scientific Center “Institute of Biology and Medicine” of Taras Shevchenko National University of Kyiv, Kyiv, Ukraine https://orcid.org/0000-0001-9614-5762

DOI:

https://doi.org/10.18370/2309-4117.2023.68.36-42

Keywords:

reproductive age, bacterial vaginosis, anti-relapse therapy, cholecalciferol, 25-hydroxyvitamin D

Abstract

Research objectives: to evaluate the effect of vitamin D supplementation (Olidetrim) in the complex anti-relapse therapy of bacterial vaginosis (BV) in women of reproductive age.
Materials and methods. The study included 63 women of reproductive age with BV and with a level of 25-hydroxyvitamin D below 75 nmol/l, who were divided into groups: the main group included 32 women who were prescribed standard therapy (metronidazole 500 mg twice a day for 7 days) and cholecalciferol (Olidetrim) 4000 IU/day with subsequent continuation of its intake in a dose 2000 IU/day for up to 6 months; the comparison group included 31 women, who were not intake vitamin D preparation during the standard therapy and during the next 6 months of observation.
After treatment, women provided completed questionnaires and self-collected vaginal swabs 1, 3, and 6 months after beginning of the study or before BV relapse. Evaluation of Gram-stained smears was carried out by microscopy according to Hay/Ison criteria, where BV corresponded to type III. The level of 25-hydroxyvitamin D in blood serum was determined by the chemiluminescent immunoassay method before the start of the
study and at 3 and 6 months of follow-up.
The primary endpoint was BV recurrence at any post-treatment interval; the patients were offered a second treatment in this case.
Results. Vitamin D deficiency at the beginning of the study was detected in 12 (37.5%) patients of the main group and in 13 (41.94%) women of the comparison group, an insufficient level – in 20 (62.5%) patients of the main group and in 58.06% women of the comparison group.
Patients complained of pathological vaginal discharge, itching, burning and dyspareunia lasting from 1 week to 2 months. At the seven-day course of basic BV therapy all participants noted the normalization of discharge and the absence of vaginal discomfort. Positive dynamics were also observed according to the gynecological examination.
One month after the treatment, 4 (12.5%) participants of the main and 6 (19.36%) women of the comparison group noted the recovery of symptoms. Absence of BV recurrence after 3 months was noted by 25 (78.12%) women of the main group and 16 (51.61%) women of the comparison group (p = 0.054), that was confirmed by the laboratory tests. At the same time, the level of 25-hydroxyvitamin D in the main group increased by 43.37% (p = 0.05), and in the comparison group it did not differ from the initial level. There were no complaints in 24 (75.0%) patients after 6 months, however, a laboratory-confirmed normal state of the vaginal microbiome was observed in 22 (70.96%) participants of the main group and in 14 (45.16%, p = 0.07) women of the comparison group. Continuation of vitamin D intake at a dose of 2000 IU/day for the next 3 months demonstrated maintenance of the 25-hydroxyvitamin D level within normal values (81.7 ± 6.23 nmol/l in the main group vs. 38.51 ± 5.43 nmol/l in comparison group, p = 0.05).
Conclusions. A decrease in the frequency of BV recurrences in women during support a normal level of vitamin D was found, which allows recommending the inclusion of cholecalciferol supplementation (Olidetrim) in the standard treatment. In patients with recurrent BV a long-term monitoring of the serum level of vitamin D is advisable in order to timely prescribe supplementation.

Author Biographies

T.F. Tatarchuk, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department;
Chief researcher, Department of Reproductive Health

L.V. Kalugina, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

MD, leading researcher, Endocrine Gynecology Department

T.I. Kvasha, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

PhD, senior researcher, Endocrine Gynecology Department

R.O. Mnevets, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; Educational and Scientific Center “Institute of Biology and Medicine” of Taras Shevchenko National University of Kyiv, Kyiv

Intern;
Assistant, Anatomy and pathological physiology department

References

  1. Adams, J.S., Ren, S., Liu, P.T., et al. “Vitamin D-directed rheostatic regulation of monocyte antibacterial responses.” J Immunol 182 (2009): 4289–95. DOI: 10.4049/jimmunol.0803736
  2. Aghajafari, F., Nagulesapillai, T., Ronksley, P., et al. “Association between maternal serum 25-Hydroxyvitamin D level and pregnancy and neonatal out-comes.” Obstetric Anesthesia Digest 34.2 (2014): 115–6. DOI: 10.1136/bmj.f1169
  3. Amegah, A.K., Klevor, M.K., Wagner, C.L. “Maternal vitamin D insufficiency and risk of adverse pregnancy and birth outcomes: a systematic review and meta-analysis of longitudinal studies.” PLoS One 12.3 (2017): e0173605. DOI: 10.1371/journal.pone.0173605
  4. Azizieh, F., Alyahya, K.O., Raghupathy, R. “Association between levels of vitamin D and inflammatory markers in healthy women.” J Inflamm Res 9 (2016): 51–7. DOI: 10.2147/JIR.S103298
  5. Bhan, I., Camargo, C.A. Jr, Wenger, J., et al. “Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults.” J Allergy Clin Immunol 127.5 (2011): 1302–4. DOI: 10.1016/j.jaci.2010.12.1097
  6. Bodnar, L.M., Krohn, M.A., Simhan, H.N. “Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy.” J Nutr 139 (2009): 1157–61. DOI: 10.3945/jn.108.103168
  7. Bradshaw, C.S., Morton, A.N., Hocking, J., et al. “High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.” J Infect Dis 193 (2006): 1478–86. DOI: 10.1086/503780
  8. Cermisoni, G.C., Alteri, A., Corti, L., et al. “Vitamin D and Endometrium: A Systematic Review of a Neglected Area of Research.” Int J Mol Sci 19.8 (2018): 2320. DOI: 10.3390/ijms19082320
  9. Chesney, R.W. “Vitamin D and the magic mountain: The anti-infectious role of the vitamin.” J Pediatr 156 (2010): 698–703. DOI: 10.1016/j.jpeds.2010.02.002
  10. Christakos, S., Ajibade, D.V., Dhawan, P., et al. “Vitamin D: metabolism.” Endocrinol Metab Clin North Am 39.2 (2010): 243–53. DOI: 10.1016/j.ecl.2010.02.002
  11. Christakos, S., Dhawan, P., Benn, B., et al. “Vitamin D: molecular mechanism of action.” Ann N Y Acad Sci 1116 (2007): 340–8.
  12. Christakos, S., Dhawan, P., Verstuyf, A. “Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.” Physiol Rev 96.1 (2016): 365–408. DOI: 10.1152/physrev.00014.2015
  13. Christesen, H.T., Falkenberg, T., Lamont, R.F., et al. “The impact of vitamin D on pregnancy: A systematic review.” Acta Obstet Gynecol Scand 91.12 (2012): 1357–67. DOI: 10.1111/aogs.12000
  14. Chu, T.W., Jhao, J.Y., Lin, T.J., et al. “Vitamin D in gynecological diseases.” J Chin Med Assoc 84.11 (2021): 1054–9. DOI: 10.1097/JCMA.0000000000000607
  15. Cohen, C.R., Wierzbicki, M.R., French, A.L., et al. “Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.” N Engl J Med 382.20 (2020): 1906–15.
  16. Dixon, B.M., Barker, T., McKinnon, T., et al. “Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults.” BMC Res Notes 24.5 (2012): 575. DOI: 10.1186/1756-0500-5-575
  17. Dunlop, A.L., Taylor, R.N., Tangpricha, V., et al. “Maternal vitamin D, folate, and polyunsaturated fatty acid status and bacterial vaginosis during pregnancy.” Infect Dis Obstet Gynecol (2011): 216–7. DOI: 10.1155/2011/216217
  18. Dunlop, A.L., Jordan, S.L., Ferranti, E.P., et al. “Total and Free 25-Hydroxy-Vitamin D and Bacterial Vaginosis in Pregnant African American Women.” Infect Dis Obstet Gynecol (2019): 9426795. DOI: 10.1155/2019/9426795
  19. Frew, L., Makieva, S., McKinlay, A.T., et al. “Human cathelicidin production by the cervix.” PLoS One 9.8 (2014): e103434. DOI: 10.1371/journal.pone.0103434
  20. Gombart, A.F., Bhan, I., Borregaard, N., et al. “Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis.” Clin Infect Dis 48 (2009): 418–24. DOI: 10.1086/596314
  21. Hanson, L., VandeVusse, L., Jerme, M., et al. “Probiotics for treatment and prevention of urogenital infections in women: a systematic review.” J Midwifery Womens Health 61 (2016): 339–55. DOI: 10.1111/jmwh.12472
  22. Harvey, N.C., Holroyd, C., Ntani, G., et al. “Vitamin D supplementation in pregnancy: a systematic review.” Health Technol Assess 18.45 (2014): 1–190. DOI: 10.3310/hta18450
  23. Hensel, K.J., Randis, T.M., Gelber, S.E., et al. “Pregnancy-specific association of vitamin D deficiency and bacterial vaginosis.” Am J Obstet Gynecol 204 (2011): 41–9. DOI: 10.1016/j.ajog.2010.08.013
  24. Hoe, E., Nathanielsz, J., Toh, Z.Q., et al. “Anti-inflammatory effects of vitamin D on human immune cells in the context of bacterial infection.” Nutrients 8 (2016): 806–19. DOI: 10.3390/nu8120806
  25. Jarzębski, T., Baczyńska, M., Kalinka, J. “Potencjalna rola peptydów antydrobnoustrojowych oraz witaminy D w leczeniu Bacterial Vaginosis.” GinPolMedProject 4.34 (2014): 42–52.
  26. Jefferson, K.K., Parikh, H.I., Garcia, E.M., et al. “Relationship between Vitamin D status and the vaginal microbiome during pregnancy.” J Perinatol 39.6 (2019): 824–36. DOI: 10.1038/s41372-019-0343-8
  27. McClelland, R.S., Balkus, J.E., Lee, J., et al. “Randomised trial of periodic presumptive treatment with high dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women.” J Infect Dis 211 (2015): 1875–82. DOI: 10.1093/infdis/jiu818
  28. Mojtahedi, S.F., Mohammadzadeh, A., Mohammadzadeh, F., et al. “Association between bacterial vaginosis and 25-Hydroxy vitamin D: a case-control study.” BMC Infect Dis 23.1 (2023): 208. DOI: 10.1186/s12879-023-08120-3
  29. Moore, K.R., Harmon, Q.E., Baird, D.D. “Serum 25-Hydroxyvitamin D and Risk of Self-Reported Bacterial Vaginosis in a Prospective Cohort Study of Young African American Women.” J Womens Health (Larchmt) 27.10 (2018): 1278–84. DOI: 10.1089/jwh.2017.6804
  30. Muzny, C.A., Sobel, J.D. “The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment.” Antibiotics (Basel) 11.4 (2022): 500. DOI: 10.3390/antibiotics11040500
  31. Parker, L., Levinger, I., Mousa, A., et al. “Plasma 25-Hydroxyvitamin D Is Related to Protein Signaling Involved in Glucose Homeostasis in a Tissue- Specific Manner.” Nutrients 8.10 (2016): 631. DOI: 10.3390/nu8100631
  32. Peebles, K., Velloza, J., Balkus, J.E., et al. “High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis.” Sex Transm Dis 46.5 (2019): 304–11. DOI: 10.1097/OLQ.0000000000000972
  33. Powell, A.M., Shary, J.R., Louden, C., et al. “Association of Bacterial Vaginosis with Vitamin D in Pregnancy: Secondary Analysis from the Kellogg Pregnancy Study.” Am J Perinatol Rep 9 (2019): 226–34. DOI: 10.1055/s-0039-1693163
  34. Qin, L.L., Lu, F.G., Yang, S.H., et al. “Does maternal vitamin D deficiency increase the risk of preterm birth: a meta-analysis of observational studies.” Nutrients 8.5 (2016): 301. DOI: 10.3390/nu8050301
  35. Ravel, J., Moreno, I., Simón, C. “Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease.” Am J Obstet Gynecol 224.3 (2021): 251–7. DOI: 10.1016/j.ajog.2020.10.019
  36. Redelinghuys, M.J., Geldenhuys, J., Jung, H., Kock, M.M. “Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities.” Front Cell Infect Microbiol 10 (2020): 354. DOI: 10.3389/fcimb.2020.00354
  37. Sherrard, J., Wilson, J., Donders, G., et al. “2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge.” Int J STD AIDS 29.13 (2018): 1258–72. DOI: 10.1177/0956462418785451
  38. Taheri, M., Baheiraei, A., Foroushani, A.R., et al. “Treatment of vitamin D deficiency is an effective method in the elimination of asymptomatic bacterial vaginosis: a placebo-controlled randomized clinical trial.” Indian J Med Res 141.6 (2015): 799–806. DOI: 10.4103/0971-5916.160707
  39. Turner, A.N., Carr Reese, P., Fields, K.S., et al. “A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis.” Am J Obstet Gynecol 211.5 (2014): 479. DOI: 10.1055/s-0039-1693163
  40. Unemo, M., Bradshaw, C.S., Hocking, J.S., et al. “Sexually transmitted infections: challenges ahead.” Lancet Infect Dis 17.8 (2017): e235-e279.
  41. Vieira-Baptista, P., Stockdale, C.K., Sobel, J. “International Society for the Study of Vulvovaginal Disease recommendations for the diagnosis and treatment of vaginitis.” Lisbon: Admedic (2023). DOI: 10.59153/adm.rdtv.001
  42. Wagner, C.L., Baggerly, C., McDonnell, S., et al. “Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009- 2011 rates.” J Steroid Biochem Mol Biol 155 (2016): 245–51. DOI: 10.1016/j.jsbmb.2015.10.022
  43. Yarbrough, V.L., Winkle, S., Herbst-Kralovetz, M.M. “Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications.” Hum Reprod Update 21.3 (2015): 353–77. DOI: 10.1093/humupd/dmu065
  44. Tatarchuk, T.F., Kalugina, L.V., Petrova, G.A., et al. “Vaginal discharge syndrome. Problem with many unknowns.” Reproductive endocrinology 3.53 (2020): 102–8. DOI: 10.18370/2309-4117.2020.53.102-108

Downloads

Published

2023-06-30

How to Cite

Tatarchuk, T., Kalugina, L., Kvasha, T., & Mnevets, R. (2023). Vitamin D supplementation in bacterial vaginosis. REPRODUCTIVE ENDOCRINOLOGY, (68), 36–42. https://doi.org/10.18370/2309-4117.2023.68.36-42

Issue

No. 68 (2023)

Section

Gynecology

License

Copyright (c) 2023 Т.Ф. Татарчук, Л.В. Калугіна, Т.І. Кваша, Р.О. Мневець

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.